Intellia Therapeutics, Inc (NTLA)

About Intellia Therapeutics, Inc

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Latest reported results

Intellia Therapeutics, Inc. reported revenue of $7.7 million for Q2 FY2026, down 46.2% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 317 institutions reported holding NTLA, with 143.6 million shares worth $2.4 billion in aggregate. The largest reported holders were ARK Invest, BlackRock and Vanguard. Of the 5 largest reported holders, all 5 added shares during the quarter.

More on NTLA

• NTLA sentiment: whether news and social coverage of Intellia Therapeutics, Inc leans bullish or bearish, and the stories driving it.
• NTLA ownership: all 317 reporting institutions, plus insider and congressional trades.
• NTLA financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.

Frequently asked questions